

Endometriosis classification, staging and reporting systems: a review on the road to a universally accepted endometriosis classification^{†,‡}

International working group of AAGL, ESGE, ESHRE and WES,
Nathalie Vermeulen  ¹, **Mauricio S. Abrao** ^{2,3}, **Jon I. Einarsson** ⁴,
Andrew W. Horne  ⁵, **Neil P. Johnson** ⁶, **Ted T.M. Lee** ⁷,
Stacey Missmer ^{8,9,10}, **John Petrozza**  ¹¹, **Carla Tomassetti** ¹²,
Krina T. Zondervan ^{13,14}, **Grigoris Grimbizis** ¹⁵, and
Rudy Leon De Wilde  ^{16,*}

¹ESHRE, Central Office, Grimbergen, Belgium ²Disciplina de Ginecologia, Departamento de Obstetricia e Ginecologia, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, Brazil ³Gynecologic Division, BP - A Beneficencia Portuguesa de São Paulo, São Paulo, SP, Brazil ⁴Division of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA ⁵University of Edinburgh, MRC Centre for Reproductive Health, QMRI, Edinburgh, UK ⁶Repromed Auckland, Remuera, Auckland, New Zealand ⁷Department of Obstetrics, Gynecology and Reproductive Sciences, Magee Womens Hospital of UPMC, Pittsburgh, PA, USA ⁸Department of Obstetrics, Gynecology and Reproductive Biology, Michigan State University College of Human Medicine, East Lansing, MI, USA ⁹Department of Epidemiology, Harvard University T H Chan School of Public Health, Boston, MA, USA ¹⁰World Endometriosis Research Foundation, WERF, London, UK ¹¹Department of Obstetrics and Gynecology, Massachusetts General Hospital Fertility Center, Boston, MA, USA ¹²Department of Obstetrics and Gynaecology, University Hospital Leuven, Leuven University Fertility Centre, Leuven, Belgium ¹³Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford Endometriosis CaRe Centre, Oxford, Oxfordshire, UK ¹⁴University of Oxford, Wellcome Centre for Human Genetics, Oxford, UK ¹⁵1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece ¹⁶Carl von Ossietzky Universität Oldenburg, University Hospital for Gynecology, Oldenburg, Germany

*Correspondence address. University Hospital for Gynecology, Pius-Hospital Oldenburg, Carl von Ossietzky University of Oldenburg, Georgstreet 12, 26121 Oldenburg, Germany. Tel: +49-441-229-1500; E-mail: rudy-leon.dewilde@pius-hospital.de; guidelines@eshre.eu 
<https://orcid.org/0000-0001-5759-9745>

Submitted on June 02, 2021; resubmitted on June 11, 2021; editorial decision on June 11, 2021

STUDY QUESTION: Which endometriosis classification, staging and reporting systems have been published and validated for use in clinical practice?

SUMMARY ANSWER: Of the 22 endometriosis classification, staging and reporting systems identified in this historical overview, only a few have been evaluated, in 46 studies, for the purpose for which they were developed.

WHAT IS KNOWN ALREADY: In the field of endometriosis, several classification, staging and reporting systems have been developed.

PARTICIPANTS/MATERIALS, SETTING, METHODS: A systematic PUBMED literature search was performed. Data were extracted and summarized.

MAIN RESULTS AND THE ROLE OF CHANCE: Twenty-two endometriosis classification, staging and reporting systems have been published between 1973 and 2021, each developed for specific, and different, purposes. There still is no international agreement on how to describe the disease. Studies evaluating the different systems are summarized showing a discrepancy between the intended and the evaluated purpose, and a general lack of validation data confirming a correlation with pain symptoms or quality of life for any of the current systems. A few studies confirm the value of the ENZIAN system for surgical description of deep endometriosis. With regards to infertility, the endometriosis fertility index has been confirmed valid for its intended purpose.

LARGE SCALE DATA: NA.

[†]ESHRE pages content is not externally peer reviewed. The manuscript has been approved by the Executive Committee of ESHRE.

[‡]This article is published simultaneously, with permission, in HROpen, FACTS, VIEWS & VISION in Obgyn and Journal of Minimally Invasive Gynecology.

© The Author(s) 2021. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

LIMITATIONS, REASONS FOR CAUTION: The literature search was limited to PUBMED. Unpublished classification, staging or reporting systems, or those published in books were not considered.

WIDER IMPLICATIONS OF THE FINDINGS: It can be concluded that there is no international agreement on how to describe endometriosis or how to classify it, and that most classification/staging systems show no or very little correlation with patient outcomes. This overview of existing systems is a first step in working toward a universally accepted endometriosis classification.

STUDY FUNDING/COMPETING INTEREST(S): The meetings and activities of the working group were funded by the American Association of Gynecologic Laparoscopists, European Society for Gynecological Endoscopy, European Society of Human Reproduction and Embryology and World Endometriosis Society. A.W.H. reports grant funding from the MRC, NIHR, CSO, Wellbeing of Women, Roche Diagnostics, Astra Zeneca, Ferring, Charles Wolfson Charitable Trust, Standard Life, Consultancy fees from Roche Diagnostics, AbbVie, Nordic Pharma and Ferring, outside the submitted work. In addition, A.W.H. has a patent Serum biomarker for endometriosis pending. N.P.J. reports personal fees from Abbott, Guerbet, Myovant Sciences, Vifor Pharma, Roche Diagnostics, outside the submitted work; he is also President of the World Endometriosis Society and chair of the trust board. S.M. reports grants and personal fees from AbbVie, and personal fees from Roche outside the submitted work. C.T. reports grants, non-financial support and other from Merck SA, non-financial support and other from Gedeon Richter, non-financial support from Ferring Pharmaceuticals, outside the submitted work and without private revenue. K.T.Z. reports grants from Bayer Healthcare, MDNA Life Sciences, Roche Diagnostics Inc, Volition Rx, outside the submitted work; she is also a Board member (Secretary) of the World Endometriosis Society and World Endometriosis Research Foundation, Research Advisory Board member of Wellbeing of Women, UK (research charity), and Chair, Research Directions Working Group, World Endometriosis Society. The other authors had nothing to disclose.

TRIAL REGISTRATION NUMBER: NA.

Key words: endometriosis / infertility / classification / staging / reporting / surgery

What does this mean for patients?

Since 1973, clinicians have proposed classification systems for endometriosis, and so far 22 different systems have been developed. Some of these systems focus on symptoms, while others have been developed to document the surgical observations, or predict the outcomes after treatment. Ideally, classification systems are evaluated in a research project to confirm it is useful in clinical management. We found that of the 22 classification systems, few have been evaluated for the purpose for which they were developed. From this review, it can be concluded that there is no international agreement on how to describe endometriosis or how to classify it.

Introduction

Endometriosis is an inflammatory estrogen-dependent disease associated with chronic pelvic pain and/or infertility that is characterized by lesions of endometrial-like tissue outside of the uterus (Johnson et al., 2017). The disease is usually confined to the abdominal cavity but, rarely, extra-abdominal lesions have been detected in the lungs, brain and even in the eye. Within the pelvic cavity, the variety of presentations is extensive with lesions detected on the peritoneum, within the ovaries (endometrioma), around the uterus, but also affecting the urinary tract, bowel, and vagina. Most definitions, but not all, consider adenomyosis (similar lesions arising within the myometrium) as a separate disease (Zegers-Hochschild et al., 2017).

Traditionally, three phenotypes of endometriosis lesions are recognized; peritoneal, ovarian (endometrioma) and deep endometriosis (DE) (Working group of ESGE ESHRE and WES et al., 2020a,b; Working group of ESGE ESHRE and WES et al., 2017a,b). Symptoms include chronic pelvic pain (dysmenorrhea, acyclic pelvic pain, dyspareunia, dyschezia, dysuria) with severity ranging from mild to debilitating, infertility, and non-specific symptoms (fatigue), but endometriosis can also be asymptomatic (Zondervan et al., 2020). Treatment options for pain include


different medical and hormonal treatments or surgery, while for infertility, surgery and/or ART have been used.

Since the first descriptions of endometriosis, this spectrum of lesions and symptoms has urged clinicians to attempt to classify the disease into informative subgroups or hierarchical stages. By definition, classification entails a systematic arrangement of similar entities on the basis of certain differing characteristics (Miller-Keane and O'Toole, 2005). When disease classification can be related to treatment outcomes or prognosis, the system is considered a staging system.

In the field of endometriosis, several classification, staging and reporting systems have been developed. The current paper provides, based on an assessment of published studies, a historical overview of these different systems. Validation studies and published reports on the implementation of the different classification, staging and reporting systems have been summarized to highlight the uptake, benefits and drawbacks of published systems for endometriosis.

Materials and methods

A literature review was performed collecting studies and reports focusing on 'endometriosis' and 'classification, staging, or scoring'.



¹ The recent paper on #ENZIAN was included, although published after the inclusion deadline.

² Non-English language studies, animal studies and papers not focusing on endometriosis.

³ Exclusion criteria included: Full text not able to be retrieved (*n*=9); Publication types [case report, expert opinion, editorial] (*n*=28); Relevant patients are not included [not endometriosis] (*n*=2); Relevant intervention/outcomes are not assessed [not on classification] (*n*=35); Irrelevant (*n*=6); Not English (*n*=4).

Figure 1. PRISMA flow diagram for the selection of studies describing endometriosis classification, staging and reporting systems.

PUBMED/MEDLINE was searched, and studies were included from inception (1966) up to 08 May 2020; all retrieved references were checked for relevance. Non-English language studies, animal studies and papers not focusing on endometriosis, including those focusing specifically on adenomyosis, were excluded from the retrieved references. Papers and classifications systems focusing on endometriosis but

including adenomyosis were not excluded. For the remaining references, the full-text papers were collected and assessed. Inclusion criteria included original studies focusing on endometriosis and classification, staging or reporting systems. The results of the literature search are summarized in a PRISMA flowchart (Fig. 1). The details of the final set of papers are summarized in evidence tables. The draft paper

was published for stakeholder review by all societies involved; 81 comments were tabulated in a review report and, where relevant, incorporated in the final version of the paper.

Results

The literature review retrieved 1305 references; one reference was added at a later stage. After applying the exclusion criteria, 154 full papers were assessed, of which 84 papers were excluded for the following reasons: full-text papers could not be retrieved ($n=9$), not written in English ($n=4$), inappropriate publication types (case report, expert opinion, editorial) ($n=28$) and relevant patients and/or intervention/outcomes are not assessed (not endometriosis or not classification) ($n=43$). Seventy papers were included for either describing a classification, staging or reporting system in endometriosis ($n=24$) or evaluating one ($n=46$) (Fig. 1). The systems in endometriosis described in this paper have been published as classification, staging or reporting systems, even though some were developed for stratification or subgrouping rather than classification.

Table I provides an overview of the 22 classification, staging or reporting systems identified in the literature and included in this report. The 46 studies reporting an evaluation of the different systems are listed in Table II.

Classification and staging systems

In the 1970s, the first 'classification' system for endometriosis originated from a study attempting to describe the results of conservative surgical treatment of endometriosis and hereby classify the extent of the disease and its relationship with the pregnancy rate (Acosta et al., 1973). Later, this classification system was further expanded and submitted for consideration to the American Fertility Society (AFS) (Buttram, 1978). Similarly, a system published by Kistner et al., (1977) was submitted for endorsement by AFS and the International Federation of Fertility Societies (IFFS). In 1979, AFS published a classification system on behalf of a group of experts including the leading authors of the previous systems (American Fertility Society, 1979). The AFS classification for endometriosis, and later published revised AFS (rAFS) and revised American Society for Reproductive Medicine (rASRM) classification, have been the main standard for classifying endometriosis ever since (American Fertility Society, 1979, 1985; American Society for Reproductive Medicine, 1997). The different versions of the AFS/ASRM classification system reflect the progress made in the knowledge on endometriosis.

Later attempts of surgical disease description or staging have focused on disease location—such as urinary tract endometriosis (Knabben et al., 2015)—or subtypes of the disease—such as DE (Chapron et al., 2003a; Tuttles et al., 2005; Coccia and Rizzello, 2011); the latter group includes the ENZIAN-Score for classifying DE (Tuttles et al., 2005). The recently updated #ENZIAN classification extends the previous ENZIAN score to incorporate all types of endometriosis (Keckstein et al., 2021). The EPHect standard recommended (SSF) and minimum required (MSF) were developed for recording of surgical phenotypic information on endometriosis (Becker et al., 2014).

While these classification systems mainly focused on describing the extent of disease during surgery, some attempted to link these observations to outcomes, such as pregnancy rates, after surgery (American Fertility Society, 1979, 1985; Kurata et al., 1993; American Society for Reproductive Medicine, 1997), or indicators for disease management (Chapron et al., 2003a). Another group of classification systems focused on pre-operative assessment of the extent of the disease (van der Wat et al., 2013; Lafay Pillot et al., 2014; Knabben et al., 2015; Menakaya et al., 2016; Riiskjær et al., 2017; Chattot et al., 2019; Ichikawa et al., 2020), based on either patient-reported symptoms or pre-operative imaging, or a combination of both. The ultrasound-based endometriosis staging system (UBESS) additionally aimed at predicting the complexity of endometriosis surgery (Menakaya et al., 2016), as does the adhesion scoring system in case of pelvic adhesions (Ichikawa et al., 2020).

Two systems aimed specifically at outcome prediction for endometriosis: the 'disease extent, complaints, objectives (ECO)-system', aiming to select the most appropriate management based on reported symptoms (Lasmar et al., 2012, 2015); and the endometriosis fertility index (EFI), aiming to predict the probability of natural conception after surgery (Adamson and Pasta, 2010). Finally, a recently published study 'Endogram' sets out to 'profile' endometriosis heterogeneity, based on the assessment of several disease markers in a biopsy sample, with the ultimate aim of guiding therapeutic options (Bouquet de Joliniere et al., 2019).

Replication, validation and clinical value of published systems

We retrieved 46 studies, mostly observational, reporting an evaluation of the different classification, staging or reporting systems (Table II). The aims and outcomes of the different studies varied significantly.

Of the included studies, eight reported on the practical aspects of the classification systems, being either the feasibility, or the inter-observer and intra-observer variability. Of these, seven studies focused on the rASRM classification system (Candiani et al., 1990; Canis et al., 1992; Hornstein et al., 1993; Rock, 1995; Lin et al., 1998; Schliep et al., 2012, 2017), while the most recent one evaluated the reproducibility of the EFI (Tomassetti et al., 2020). Early studies (1990s) reported significant variability in rAFS classification by five independent experts reviewing surgery recordings, specifically with regards to endometriosis of the ovary and cul-de-sac obliteration (Hornstein et al., 1993), although another study from the same period reported good to fair agreement in scoring endometriosis between two experts using photographs or recordings (Rock, 1995). In more recent studies, the rASRM classification system was found to have acceptable inter-observer agreement and inter-rater reliability among surgeons and experts reviewing surgical photographs and/or recordings (Schliep et al., 2012, 2017). Studies have also focused on the feasibility of specific aspects of the AFS/rAFS/rASRM classification, specifically classifying bilateral adnexal disease (Canis et al., 1992), measuring cyst diameter (Candiani et al., 1990), or the reliability of laparoscopic versus laparotomic scoring (Lin et al., 1998). For the EFI, a near perfect clinical agreement rate between two independent experts (1.00, 95% CI 0.956–1.000) and high agreement between two assessments by the same expert (0.988, 95% CI 0.934–1.000) has been reported (Tomassetti et al., 2020).

Table 1 Historical overview of endometriosis classification/staging systems.

Endometriosis classification/staging system	Classification/staging based on	Intended purpose	Details	Reference
#ENZIAN classification	2021 Surgical observation or imaging	✓	Non-invasive and surgical description system for endometriosis	Keckstein <i>et al.</i> (2021)
Adhesion scoring system	2020 US	✓	Pre-operative prediction of the pelvic adhesion status	Ichikawa <i>et al.</i> (2020)
ENDOGRAM	2019 Disease markers in biopsy sample	✓	Analysis of endometriotic tissues supporting therapeutic decisions	Bouquet de Joliniere <i>et al.</i> (2019)
ENDORECT	2019 Clinical examination, US, MRI	✓	Preoperative score to predict rectosigmoid involvement	Chattor <i>et al.</i> (2019)
Bowel Endometriosis Syndrome (BENS) score	2017 Symptoms	✓	Identify bowel endometriosis syndrome based on patient reported symptoms and QoL	Riisjær <i>et al.</i> (2017)
Preoperative ultrasound-based endometriosis staging system (UBESS)	2016 US	✓	Pre-operative staging and prediction of the level of complexity of laparoscopic surgery.	Menakaya <i>et al.</i> (2016)
Classification of ureteral endometriosis EPHect SSF—EPHect MSF (surgical form)	2015 Surgical observation	✓	Clinical classification of urinary tract endometriosis	Knabben <i>et al.</i> (2015)
Clinical score	2014 Symptoms	✓	Recording of surgical phenotypic information and related sample collections obtained at laparoscopy	Becker <i>et al.</i> (2014)
			Predict DE presence before endometrioma surgery	Lafay Pillat <i>et al.</i> (2014)

(continued)

Table I Continued

Classification/staging system	Publication year	Intended purpose	Details	Reference
LSD/MURÖ Classification	2013	Classification/staging based on Modified Virtual Colonoscopy	Descriptive imaging classification, with implied severity for recto-genital and disseminated endometriosis	van der Wat et al. (2013)
EECO system	2012	Description Extent, symptoms and objectives	Determine most appropriate management	Lasmar et al. (2012), Lasmar et al. (2015)
Deep endometriosis staging form	2011	Staging US	Staging system for DE based on ultrasonographic finding	Coccia and Rizzello (2011)
Endometriosis Fertility Index (EFI)	2010	Assessment/pre-operative Surgical observation + Patient parameters	Prediction of (non-)IVF pregnancy after surgery	Adamson and Pasta (2010)
ENZIAN Classification	2005	Assessment Surgical observation (or MRI)	Surgical classification for DE	Keckstein et al. (2012), Turtiles et al. (2005)
Chapron Classification	2003	Assessment Surgical observation	Surgical classification for DE with suggested operative procedure	Chapron et al. (2003a), Chapron et al. (2003b)
Revised ASRM Classification	1997	Assessment Surgical observation	Adapted from rAFS score	American Society for Reproductive Medicine (1997)
TOP classification	1993	Assessment Surgical observation	Evaluate the severity of endometriosis by site, i.e., fallopian tubes (T), ovaries (O) and the peritoneum (P) and impact on PR	Kurata et al. (1993)

(continued)

Table I Continued

Endometriosis classification/staging system	Classification/staging based on	Intended purpose	Details	Reference
Revised American Fertility Society (rAFS) classification	1985 Surgical observation	Prediction of difficulty of surgery	✓	American Fertility Society (1985)
American Fertility Society (AFS) classification	1979 Surgical observation	Treatment selection	✓	American Fertility Society (1979)
Butram classification	1978 Surgical observation	Staging	✓	Butram (1978)
Kistner classification	1977 Surgical observation	Description of disease	✓	Kistner et al. (1977)
Acosta classification	1973 Surgical observation	Assessment/pre-operative prediction of pain relief/improved QoL	✓	Acosta et al. (1973)
		Prediction of conception		#ENZIAN, the recently updated ENZIAN classification, which incorporates all types of endometriosis; DE, deep endometriosis; ECO, disease extent complaints, objectives system; PR, pregnancy rate; QoL, quality of life; US, ultrasound.

¹In case of ENZIAN score based on MRI.

Table II Overview of replication, validation and clinical value of published systems.

		Main results	Reference
ENZIAN	Description	Population source	
	Aim of the study	Sample size	
	Age mean (range or SD)	Case detection	
	Intergroup agreement	Histologic confirmation	
	Feasibility	ENZIAN A2, C1, C3 and FA were risk factors for the length of hospital stay.	Nicolaus et al. (2020)
	Prediction of complication rate/mediation of pain/QoL		
	Staging		
	Treatment selection		
	of surgery/complication rate		
	Assessment/pre-operative diagnosis/perioperative prediction of difficult		
	Diagnosis/pre-operative assessment		
	Feasibility		Burla et al. (2019)
	Prediction of complication rate/mediation of pain/QoL		
	Intergroup agreement		
	Age mean (range or SD)		
	Population source		
	Aim of the study		
	Sample size		
	Case detection		
	Intergroup agreement		
	Feasibility		
	Prediction of complication rate/mediation of pain/QoL		
	Staging		
	Treatment selection		
	of surgery/complication rate		
	Assessment/pre-operative diagnosis/perioperative prediction of difficult		
	Diagnosis/pre-operative assessment		
	Feasibility		Morgan-Ortiz et al. (2018)
	Prediction of complication rate/mediation of pain/QoL		
	Intergroup agreement		
	Age mean (range or SD)		
	Population source		
	Aim of the study		
	Sample size		
	Case detection		
	Intergroup agreement		
	Feasibility		
	Prediction of complication rate/mediation of pain/QoL		
	Staging		
	Treatment selection		
	of surgery/complication rate		
	Assessment/pre-operative diagnosis/perioperative prediction of difficult		
	Diagnosis/pre-operative assessment		
	Feasibility		Di Paola et al. (2015)

(continued)

Table II Continued

Assessment/pre-operative Diagnosis/pain/QoL Treatment selection Staging Description of surgery/complication Prediction of difficulty Prevention of pain/QoL Feasibility Intervention of conception Age mean (SD) Population source Case definition Endometriosis Reference	Main results	Reference
ENZIAN	<p>Aim of the study</p> <p>+ Operating time</p> <p>Preoperative estimation of laparoscopic operating time</p> <p>Sample size</p> <p>151 (19–53 years)</p> <p>Single center</p> <p>Histologic confirmation</p> <p>An ENZIAN-based model for estimating operating time for DE, assuming complication-free procedures (model's predictive power: $P < 0.001$). The error of estimation for the operating time prediction is 0 ± 35.35 min (range –83 to +117 min).</p>	<p>Population source</p> <p>Case definition</p> <p>Endometriosis</p> <p>Reference</p> <p>Haas et al. (2013a)</p>
UBESS	<p>Aim of the study</p> <p>+ Correlation with RCOG laparoscopic level of complexity 1, 2, and 3</p> <p>Identification of duplicate classifications of the same lesions</p> <p>Not reported</p> <p>219</p> <p>Single center</p> <p>Histologic confirmation</p> <p>Comparison to IAFS. The severity of DE according to ENZIAN was as follows: grade 1: 45%; grade 2: 26%; grade 3: 19%; grade 4: 10%. Fifty-eight patients were classified according to ENZIAN although they did not fulfill the criteria of DE and had previously been classified according to the IAFS classification.</p> <p>Adaptation of the ENZIAN score would reduce the diagnoses of DE by 36% (95% CI: 29–44%).</p>	<p>Population source</p> <p>Case definition</p> <p>Endometriosis</p> <p>Reference</p> <p>Haas et al. (2011)</p>

(continued)

Table II Continued

	Main results	Reference
Assessments/pre-operative		
Diagnoses/pre-operative		
Staging		
Treatment selection		
Prediction of difficulty of surgery/complexity	+	
Prediction of pain/remediation/QoL	surgical skills	
Feasibility		
Interobserver agreement		
Sample size	Validation for predicting the correct RANZCOG/AGES' laparoscopic skill level.	
Age mean (range or SD)	155 (8.6)	
Population source	Multi-center	
Endometriosis	history of chronic pelvic pain and/or endometriosis	
Case definition	The accuracy, sensitivity, specificity, PPV and NPV, and positive and negative likelihood ratios of the UBESS I to predict the RANZCOG/AGES surgical skill levels 1/2 were 99.4%, 98.9%, 100%, 100%, 98.2%, not applicable, and 0.01; those of UBESS II to predict surgical skill levels 3/4 were: 98.1%, 96.8%, 98.4%, 93.8%, 99.2%, 60 and 0.033, and those for UBESS III to predict surgical skill level 6 were: 98.1%, 97.2%, 99.2%, 97.2%, 99.2%, 115.7, and 0.028. The rate of correctly predicting the exact level of skills needed was 98.1%, and Cohen's kappa statistic for the agreement between UBESS prediction and levels of training required at surgery was 0.97, indicating almost perfect agreement.	
UBESS		
EFI	+ Accuracy for the prediction of non-ART pregnancy	
	4598 NA NA	
		Cumulative non-ART pregnancy rate at 36 months increased from 10% (95% CI: 3, 16%) in women with EFI score 0–2 to 69% (95% CI: 58, 79%) in women with EFI score 9–10, with a significant increase for each score category (0–2, 3–4, 5–6, 7–8, 9–10)
		Vesaliet al. (2020) Meta-analysis

(continued)

Table II Continued

Assessment/pre-operative	Description	Staging	Treatment selection	Predictive difficulty of surgery/complication	Predictive pain	Premedication/QoL	Predictive of conception	Feasibility	Informed consent	Sample size	Population source	Endometriosis	Main results	Reference	
EFI															

(continued)

Table II Continued

Assessment/pre-operative	Description	Staging	Treatment selection	Prediction of difficulty of surgery/complication	Predictor of pain/Prediction/QoL	Feasibility	Sample size (range mean SD)	Population source	Endometriosis Case definition	Main results	Reference
EFI	Accuracy for the prediction of non-ART pregnancy	+ +	Accuracy for the prediction of non-ART pregnancy	68 1097	>> 29.8 years (20–46)	Single-center Single center	Surgical confirmation Surgical confirmation	The mean EFI scores of 68 women who were not pregnant and pregnant were 5.43 ± 0.36 and 6.88 ± 0.28, respectively. The relation between EFI and natural pregnancy was significant (cumulative overall PR, p = 0.006), whereas a FS stage was not (univariate logistics, P = 0.853). The cut-point for maximum natural pregnancy outcomes was 6 (area under ROC curve = 0.710, 95% CI 0.586–0.835).	The mean EFI scores of 68 women who were not pregnant and pregnant were 5.43 ± 0.36 and 6.88 ± 0.28, respectively. The relation between EFI and natural pregnancy was significant (cumulative overall PR, p = 0.006), whereas a FS stage was not (univariate logistics, P = 0.853). The cut-point for maximum natural pregnancy outcomes was 6 (area under ROC curve = 0.710, 95% CI 0.586–0.835).	Kim et al. (2019)*	
									Zhang et al. (2018)*		
									Maheux-Lacroix et al. (2017)*		

(continued)

Table II Continued

Assessment/pre-operative diagnosis	Description	Staging	Treatment selection	Prediction of difficulty of surgery/complication	Prediction of pain relief/Goal remediation	Predictive of conception/Quality of life improvement	Aim of the study	Sample size	Age mean (range or SD)	Population source	Case definition	Main results	Reference
EFI							+ Accuracy for the prediction of non-ART pregnancy and ART pregnancy	196	32.3 years (SD 4.8)	Single center	Surgical confirmation	The cumulative PR was 76%. The PR, non-ART PR and ART PR for EFI ≤ 1 were 42.3%, 30.5% and 60.6%; 5–6, 67.9%, 30.5% and 60.6%; and for EFI ≥ 7 , 87.7% 48.2% and 80.3%, respectively. The benefit of ART was inversely correlated with the mean EFI score. On multivariate analysis, the EFI score was significantly associated with non-ART pregnancy (OR, 1.629, 95% CI 1.235–2.150).	Boujenah et al. (2017)*
							+ Accuracy for the prediction of non-ART pregnancy + use for treatment selection (Surgery vs surgery + IVF-ET)	345	32.2 years (22.0–45.0)	Single center	Histologic confirmation	Significant differences in spontaneous PRs among different EFI scores were identified ($\chi^2 = 29.945$; $P < 0.05$). The least function score was proved to be the most important factor for EFI. In patients with an EFI score ≥ 5 after 12 months from surgery, the cumulative PRs of those who received both surgery and IVF-ET were much higher than the spontaneous PRs of those who received surgery alone ($\chi^2 = 4.16$; ns).	Li et al. (2017)*
							+ ART outcome	412	32.5 years (SD 4.6)	Single center	Histologic confirmation	A significant relationship between EFI and spontaneous PR was observed at 12 months ($P = 0.001$). The least function score and complete removal of endometriotic lesions and pelvic adhesions were significantly associated with spontaneous pregnancy ($P = 0.006$). Cumulative PR at 18 months was 78.8%. ART benefits were higher for patients with poor EFI.	Boujenah et al. (2015)*

(continued)

Table II Continued

			Main results	Reference
Assessment/pre-operative	Diagnosis/pre-operative	Description		
Treatment selection	Staging			
Prediction of difficulty of surgery/complexity of pain	Prediction of pain			
Premedication/QoL	Feasibility			
Intraoperative	Agreement			
Population source	Sample size (range or SD)			
Case definitions	Endometriosis			
Aim of the study				
EFI	+ non-ART/ ART outcome	Accuracy for the prediction of non-ART pregnancy and ART pregnancy	104 34.5 years (SD 4.5)	Surgical confirmation Differences in time to non-ART pregnancy for the six EFI groups were statistically significant (log rank, $P = 1.4 \times 10(-4)$). The AUC for EFI as ART outcome predictor was 0.75 (95% CI 0.61–0.89, $P = 6.2 \times 10(-3)$), while the best cut-point for pregnancy was 5.5.
	+ non-ART/ ART outcome	Accuracy for the prediction of non-ART pregnancy	161 32.08 years (22–40)	Surgical confirmation Comparison to rAFS; Significant differences in cumulative PRs were observed among EFI scores (IFI score 0–3, 8.3%; IFI score 4–7, 41.2%; and IFI score 8–10, 60.9%; $\chi^2 = 16.254$, $P < 0.001$). EFI scores, but not rAFS stage, predict PRs in patients with endometriosis-associated infertility.
	+ ART outcome	Ability of the EFI score and rAFS classification for predicting IVF outcomes	199 32.0 years (SD 4.2)	Histologic confirmation Comparison to rAFS; The AUC of the EFI score (AUC = 0.641, standard error (SE) = 0.039, 95% CI = 0.564–0.717, cutoff score = 6) was significantly larger than that of the rAFS classification (AUC = 0.445, SE = 0.041, and 95% CI = 0.364–0.526). The antral follicle count, estradiol level on day of hCG, number of oocytes retrieved, number of oocytes fertilized, number of cleaved embryos, implantation rate, CPR, and cumulative pregnancy rate were greater in the ≥ 6 EFI score group compared to the ≤ 5 EFI score group. EFI has more predictive power for IVF outcomes than rAFS.

(continued)

Table II Continued

Assessment/pre-operative	Description	Staging	Treatment selection	Prediction of difficulty of surgery/complication	Prediction of pain or prediction of QoL	Predictive concept of competition	Feasibility	Informed consent	Agreement	Sample size	Population source	Case definition	Main results	Reference	
EFI									+	233	31.3 years (SD 3.9)	Single center	Surgical confirmation	Highly significant relationship between EFI and the time to non-ART pregnancy ($P=0.0004$), with the KM estimate of cumulative overall PR at 12 months after surgery equal to 45.5% (95% CI 39.47–49.87) ranging from 16.6% (95% CI 5.01–47.65) for EFI scores 0–3, to 62.55% (95% CI 55.18–69.94) for EFI scores 9–10. For each increase of 1 point in the EFI score, the relative risk of becoming pregnant increased by 31% (95% CI 16–47%, i.e. HR 1.31). The least function score was found to be the most important contributor to the total EFI score.	Tomassetti et al. (2013)*
ECO system									+	166	34.0 years (SD 7.2)	2 centers	Histologic confirmation	Among patients, 78 (47.0%) were medically treated and 88 (53.0%) underwent therapeutic laparoscopy. All three patients scoring two had undergone hormonal treatment. Among 51 patients scoring 3, 49 (96.1%) were clinically managed and 2 (3.9%) underwent surgery. Among 52 patients scoring 4, 26 (50.0%) had undergone medical treatment and 26 (50.0%) surgical treatment. All 56 patients who scored 5 and the 4 patients who scored 6 underwent surgery.	Lasmari et al. (2015)

(continued)

Table II Continued

Assessment/pre-operative diagnosis/operative	Description	Staging	Treatment selection	Prediction of difficulty of surgery/complication	Prediction of pain	Predicted outcome/QoL	Feasibility of conception	Interobserver agreement	Sample size	Age mean (range or SD)	Population source	Endometriosis	Main results	Reference
rASRM/rAFS/AFS									161	32.08 years (22–40)	Single center	Surgical confirmation	Comparison to EFII: The cumulative PR 36 months after surgery was 46.3% (stage I, 53.6%; stage II, 36.0%; stage III, 51.7%; and stage IV, 41.7%; $\chi^2 = 4.143$, $P = 0.246$). In the 1st year, PRs significantly differed between patients with rAFS stage IV and those with stages I–III ($\chi^2 = 6.024$; $P = 0.014$). rAFS stage did not predict PR in patients with endometriosis-associated infertility.	Zeng et al. (2014)
									—	Ability of rAFS (vs EFII) to predict IVF outcomes	Single center	Histologic confirmation	Comparison to EFII: The AUC of the EFII score was significantly larger than that of the rAFS classification (AUC = 0.445 SE = 0.041, and 95% CI = 0.364–0.526).	Wang et al. (2013)
			— ART						401	34.8 years (SD 8.73)	Single center	Histologic confirmation	rASRM IV was a risk factors for the length of hospital stay. Clavien-Dindo Grade III complications were significantly associated with rASRM stage IV.	Nicolaus et al. (2020)

(continued)

Table II Continued

Assessment/pre-operative diagnosis/pre-operative assessment	Description	Staging	Treatment selection	Prediction of difficulty of surgery/complication of surgery/pain prediction of pain/QoL prediction of pain/QoL	Predictive conception of conceiveability of conceiveability	Feasibility	Agreement/intereobserver agreement	Sample size (range or SD)	Population source	Endometriosis diagnosis case development	Main results	Reference	
rASRM/rAFS/AFS								148	32.0 years (SD 6.7)	Single center	105 women with and 13 women without a postoperative endometriosis	Surgeons and expert reviewers had substantial agreement on diagnosis and staging after viewing digital images ($n = 148$; mean $j = 0.67$, range 0.61–0.69; mean $j = 0.64$, range 0.53–0.78, respectively) and after additionally viewing operative reports ($n = 148$; mean $j = 0.88$, range 0.85–0.89; mean $j = 0.85$, range 0.84–0.86, respectively). Although additionally viewing MRI findings ($n = 36$) did not greatly impact agreement, agreement substantially decreased after viewing histological findings ($n = 67$), with expert reviewers changing their assessment from a positive to a negative diagnosis in up to 20% of cases.	Schliep et al (2017)

(continued)

Table II Continued

Assessment/pre-operative diagnosis/operative	Description	Staging	Treatment selection	Prediction of difficulty of surgery/complication of surgery/pain	Predicted median QoL or prediction of pain	Predictive or concordance of prediction	Feasibility	Agreement	Sample size (range or SD)	Population source	Main results	Reference
rASRM/rAFS/AFS												

(continued)

Table II Continued

Assessments/pre-operative	Description	Staging	Treatment selection	Prediction of difficulty of surgery/complication	Prediction of pain	Premedication/QoL	Predictive conception	Feasibility	Informed consent	Agreeability	Sample size	Population source	Case definition	Main results	Reference	
rASRM/rAFS/AFS											148	Not reported	Single center	Not reported	The interrater reliability for endometriosis diagnosis among the 8 surgeons was substantial: Fleiss kappa = 0.69 (95% CI 0.64–0.74). Surgeons agreed on revised ASRM endometriosis staging criteria after experienced assessment in a majority of cases (mean 61%, range 52–75%) with moderate inter-rater reliability: Fleiss kappa = 0.44 (95% CI 0.41–0.47),	Schliep et al (2012)

(continued)

Table II Continued

	Main results	Reference
Assessment/pre-operative		
rASRM/rAFS/AFS		
Description		
Treatment selection	+ Association with type and severity of pain, and with symptoms after laparoscopic surgery	Milngos et al. (2006)
Staging	+ pain	
Prediction of difficulty of surgery/comPLICATION of pain/prediction QoL	- pain recurrence + relapse	
Prediction of conception/predictability	- pregnancy	
Feasibility	-	
Agreement	Predictive value for response to surgical treatment	
Sample size	537	
Age mean (range or SD)	Not reported	
Population source	Single center	
Endometriosis	Histologic confirmation	
Main results	The cumulative probability of pregnancy at 3 years from surgery was 47% (51% at stage I, 45% at stage II, 46% at stage III, and 44% at stage IV; $\chi^2 = 150$, ns). The cumulative probability of moderate or severe dysmenorrhoea recurrence in 25 symptomatic subjects was 24% (32% at stage I, 24% at stage II, 21% at stage III and 19% at stage IV; $\chi^2 = 3.39$, ns). The cumulative probability of disease relapse was 12% (3% at stage I, 11% at stage II, 11% at stage III and 23% at stage IV; $\chi^2 = 24.95$, $P = 0.0001$).	Vercellini et al. (2006)

(continued)

Table II Continued

Assessment/pre-operative diagnosis	Description	Staging	Treatment selection	Prediction of surgery/complication of surgery/complexity of pain	Prediction of pain/QoL	Feasibility or concordance of interpretation	Aim of the study	Sample size (range or SD)	Population source	Endometriosis definition	Main results	Reference
rASRM/rAFS/AFS	-			-	Impact of treatments on pain + association pain scores	Impact of treatments on pain + association pain scores	Not reported	181	Single center	Histologic confirmation	No correlation was found between the stage of endometriosis according to RAPS score and the severity of CPP.	Scindei et al. (2005)
					Variable	Comparison of laparoscopic and laparotomic scoring	Not reported	84	Single center	Surgical confirmation	There was considerable variability in laparoscopic vs laparotomic scoring by the same observer, with largest variability in ovarian endometriosis and cul-de-sac obliteration subscores, and least variability for peritoneum endometriosis. The inter-method variation was sufficient to alter the staging in 34.5% of patients, with a difference of two stages in 3.6% of patients. In general, there was fair-to-good agreement (kappa coefficient 0.49).	Lin et al. (1998)
					-	ART pregnancy	Impact of severity of endometriosis on the outcome of IVF	61	Single center	Surgical confirmation	Response to COH and the number, maturity, and quality of the oocytes was comparable between stages. Fertilization rates for oocytes of patients with stages III/IV were significantly impaired compared to those in stage I/II ($P = 0.004$). The implantation rate, CPR, and miscarriage rate were comparable between stages I/II and stages III/IV.	Pal et al. (1998)

(continued)

Table II Continued

(continued)

Table II Continued

Assessment/pre-operative	Description	Staging	Treatment selection	Prediction of difficulty of surgery/complication	Predictor of pain/predictive goal	Predictive conception rate	Feasibility	Sample size (range mean SD)	Population source	Main results	Reference
rASRM/rAFS/AFS											
Endometriosis											

The symbols should be interpreted as follows: + indicates a significant positive result in a correlation (or similar) test; – indicates a significant negative result in a correlation (or similar) test. The highlighted columns represent the intended purpose of the classification/staging system (as in Table I).

AFS, American Fertility Society; AGES, Australasian Gynaecological Endoscopy and Surgery; COH, controlled ovarian hyperstimulation; CPP, chronic pelvic pain; CTR, clinical pregnancy rate; DE, deep endometriosis; EF, endometriosis fertility index; HR, hazard ratio; IVF-ET, IVF embryo transfer; K-M, Kaplan–Meier; LBR, live birth rate; NPY, negative predictive value; PPV, positive predictive value; RANZCOG, Royal Australian and New Zealand College of Obstetricians and Gynaecologists; RR, relative risk.

*Study included in meta-analysis (Yessi et al., 2020).

($P \leq 0.01$).

Rock et al. (1981).

Candiani et al. (1990).

The AFS scale poorly specifies Guzick et al. (1982) the relation between severity of disease and pregnancy outcome after therapy. A non-parametric monotonic estimator, generating a relationship between AFS score and pregnancy following treatment is shown to improve the discriminatory power of the AFS scale.

The AFS scale poorly specifies Guzick et al. (1982) the relation between severity of disease and pregnancy outcome after therapy. A non-parametric monotonic estimator, generating a relationship between AFS score and pregnancy following treatment is shown to improve the discriminatory power of the AFS scale.

The AFS scale poorly specifies Guzick et al. (1982) the relation between severity of disease and pregnancy outcome after therapy. A non-parametric monotonic estimator, generating a relationship between AFS score and pregnancy following treatment is shown to improve the discriminatory power of the AFS scale.

The AFS scale poorly specifies Guzick et al. (1982) the relation between severity of disease and pregnancy outcome after therapy. A non-parametric monotonic estimator, generating a relationship between AFS score and pregnancy following treatment is shown to improve the discriminatory power of the AFS scale.

The AFS scale poorly specifies Guzick et al. (1982) the relation between severity of disease and pregnancy outcome after therapy. A non-parametric monotonic estimator, generating a relationship between AFS score and pregnancy following treatment is shown to improve the discriminatory power of the AFS scale.

The AFS scale poorly specifies Guzick et al. (1982) the relation between severity of disease and pregnancy outcome after therapy. A non-parametric monotonic estimator, generating a relationship between AFS score and pregnancy following treatment is shown to improve the discriminatory power of the AFS scale.

The AFS scale poorly specifies Guzick et al. (1982) the relation between severity of disease and pregnancy outcome after therapy. A non-parametric monotonic estimator, generating a relationship between AFS score and pregnancy following treatment is shown to improve the discriminatory power of the AFS scale.

The AFS scale poorly specifies Guzick et al. (1982) the relation between severity of disease and pregnancy outcome after therapy. A non-parametric monotonic estimator, generating a relationship between AFS score and pregnancy following treatment is shown to improve the discriminatory power of the AFS scale.

The AFS scale poorly specifies Guzick et al. (1982) the relation between severity of disease and pregnancy outcome after therapy. A non-parametric monotonic estimator, generating a relationship between AFS score and pregnancy following treatment is shown to improve the discriminatory power of the AFS scale.

The remaining studies ($n=37$) applied the classification or staging systems to a cohort of patients, evaluating whether the system was reliable with regards to its proposed aim, or evaluating whether the classification could be used for other purposes. The latter was mainly the case for the AFS/rAFS/rASRM classification system, which was developed for surgical staging, but has been evaluated for predicting symptom relief and recurrence after surgery (Milingos et al., 2006; Vercellini et al., 2006), complications after surgery (Nicolaus et al., 2020), ovarian reserve (Posadzka et al., 2014), time to non-ART pregnancy (Yun et al., 2015), pregnancy outcomes (Rock et al., 1981; Guzik et al., 1982) and the outcomes of ART treatment (Pal et al., 1998; Barbosa et al., 2014; Pop-Trajkovic et al., 2014). Furthermore, correlation of the AFS/rAFS/rASRM classification system with symptoms before surgery was evaluated (Marana et al., 1991; Szendei et al., 2005; Vercellini et al., 2007). To our knowledge, there are no studies specifically evaluating the feasibility or reliability of the AFS/rAFS/rASRM classification system for its proposed aim, being a descriptive system of surgical documentation of disease.

The EFI, a 10-point scoring system grouped into five categories of risk, has been assessed in 12 studies and one review. It has been mainly assessed for its intended purpose, being prediction of the probability of natural conception after surgery (Tomassetti et al., 2013; Wang et al., 2013; Zeng et al., 2014; Boujenah et al., 2015; Garavaglia et al., 2015; Boujenah et al., 2017; Li et al., 2017; Maheux-Lacroix et al., 2017; Zhang et al., 2018; Kim et al., 2019; Negi et al., 2019; Zhou et al., 2019). Interestingly, in some of these studies, an evaluation of the prognostic value of the different factors included in the EFI score was also performed. A meta-analysis summarized these validation studies and evaluated the performance of the EFI score for predicting non-ART pregnancy after endometriosis surgery, observing good predictive value with a pooled estimate for AUC of 0.71 (95%CI 0.65-0.80) (Vesali et al., 2020). Some authors have (additionally) evaluated whether its purpose can be extended to guide patient management, by using it to select patients that would benefit from ART treatments (Boujenah et al., 2015; Li et al., 2017), and/or predicting the chances of pregnancy from ART treatments (Wang et al., 2013; Garavaglia et al., 2015).

The ECO system has been validated for prediction of management (surgery or medical treatment) in a single study, by the same authors that developed the tool (Lasmar et al., 2015).

The UBESS system, developed for pre-operative staging and prediction of the complexity of surgery, was evaluated in three studies reporting on the latter purpose, i.e. difficulty of surgery (Chaabane et al., 2019; Espada et al., 2020) and prediction of surgical skill levels (Tompsett et al., 2019).

Finally, the ENZIAN classification system, developed as a descriptive system for surgical staging of DE, was evaluated for its purpose in two studies (Haas et al., 2011; Morgan-Ortiz et al., 2018). Another evaluation reported on the correlation between the ENZIAN classification and complications after surgery, classified according to the Clavien-Dindo complication grading (Nicolaus et al., 2020). The use of the ENZIAN classification system was further extrapolated for its use in pre-operative assessment with imaging. Two studies evaluated this MRI-based ENZIAN system (Di Paola et al., 2015; Burla et al., 2019), and a third study reported on a model to predict operation time based on the MRI-based ENZIAN classification (Haas et al., 2013a).

In general, published classification or staging systems have been developed with various intended purposes, ranging from diagnosis (including symptoms) and pre-operative assessment, surgical description or staging, to prediction of surgical difficulty and treatment outcomes (both for pain and infertility). The studies summarized above confirm the surgical value of the ENZIAN system for description and pre-operative assessment of DE, and of UBESS for predicting laparoscopic difficulty. However, most classification/staging systems show no or very little correlation with patient outcomes. The exception is the EFI, which has been consistently shown to provide good predictive value for natural conception after endometriosis surgery. It is notable that the development of the EFI was data driven, whereas the development of most other classification/staging systems was based on expert opinion.

Discussion

The current paper provides an overview of currently available and published classification, staging and/or reporting systems for endometriosis. We include 22 systems published between 1973 and 2021. Each of the systems was developed for a specific and different purpose. The first systems tried to classify the various forms of endometriosis that were encountered (at the time), and this remains the purpose of more recent systems as there still is no international agreement on how to describe the disease. Next, we summarize published studies evaluating the different classification, staging or reporting systems. From this, we show a discrepancy between the intended and the evaluated purpose, and a general lack of validation data confirming correlation with pain symptoms or quality of life for any of the current endometriosis classification systems. With regards to infertility, the EFI has been confirmed valid for its intended purpose of predicting the probability of natural conception after surgery.

Classification and staging systems are widely used in medicine and have been shown to be valuable in guiding clinical management. Examples include the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging systems for cancer, the Gleason score for prostate cancer, the Braak Staging for Parkinson's disease, and the ACR/EULAR Classification Criteria for Rheumatoid Arthritis. The ACR/EULAR Classification Criteria for Rheumatoid Arthritis were developed based on data analysis of 3115 patients followed by a consensus process in which determinants for risk of rheumatoid arthritis were selected and grouped into a classification system, which was further refined, and the feasibility was optimized (Aletaha et al., 2010). A review published 2 years afterwards identified 17 articles (total 6816 patients) and 17 meeting abstracts (total 4004 patients) investigating the classification criteria. Only a minority of the articles aimed to validate the system in the intended population, while the other studies extended the target population, used different reference standards or adapted the criteria in the system (Radner et al., 2014). The review findings are similar to the findings of the current review, although in a different field of medicine. The TNM staging system for cancer was developed in the early 1950s, aiming to guide clinical classification of cancer cases by anatomical extent. The philosophy and technique of TNM staging were developed by Professor Denoix and later adopted by international societies (Denoix, 1952; Sellers, 1971). The system is currently at its eighth edition (Edge et al., 2010). The system is revised

in a 6- or 8-year cycle and changes are implemented based on high-level evidence collected through large datasets. Specifications are available for different types of cancer, and the system has been complemented with a summary staging or classification linked to prognosis and used for treatment planning. In the TNM system for lung cancer, as an example, TNM staging adaptations included the removal of rare findings from the system, and corrections in stage grouping based on survival outcomes (Lim et al., 2018). In addition, the TNM system has been increasingly complemented by molecular marker data that more accurately stratify risk in patients and guide appropriate treatment options. The longevity and update systems applied for the TNM staging, and the value of additional molecular subtype identification, are likely to be important guides for the design of future endometriosis classification and staging systems that correlate with relevant patient outcomes.

Specifically, for endometriosis, previous reviews have summarized and commented on existing classification systems, mainly rASRM, ENZIAN and EFI. It has previously been concluded that the rASRM system has poor correlation with pain, fertility outcomes or prognosis, and that the ENZIAN system has poor correlation with symptoms and infertility (Haas et al., 2013b; Johnson et al., 2017; Andres et al., 2018). The EFI system needs further evaluation with regards to the importance of the different parameters and whether to include the completeness of surgical treatment (Maheux-Lacroix et al., 2017). The conclusion of previous reviews of classification systems and our overview is consistently phrased as a need for a generally accepted classification with a clear goal/purpose (Adamson, 2011; Haas et al., 2013b; Johnson et al., 2017; Andres et al., 2018; Rolla, 2019). Yet, as presented in this paper, the goal and purpose of published classification, staging or reporting systems for endometriosis is often ignored when evaluating classification or staging systems, limiting the value of the evaluation studies and of the systems in general.

To our knowledge, this is the first report comparing the outcomes assessed in the studies with the intended purposes of the classification systems. Indeed, we show that the rASRM system has been widely evaluated, often with negative conclusions, but we found no studies evaluating the system for its intended goal, which is descriptive surgical staging. ENZIAN and EFI have been evaluated for their intended purpose, but studies have also evaluated whether they can be applied more widely and for other outcomes. Apart from these three systems, only two other classification systems (UBESS and ECO) have been evaluated for their intended purpose, with no evaluations of the remaining 17 classification systems, preventing them from further dissemination and uptake.

The current review provides an overview of published classification systems and studies evaluating them, but no detailed assessment of all positive and negative aspects of the classification systems, so as not to repeat previous reviews (Johnson et al., 2017). In addition, we have restricted our overview to classification systems published in peer-reviewed papers and available through PUBMED/MEDLINE. Although locally used and/or unpublished systems are available and can be valuable, the relevance of including them in the current review was considered low, as they would not be widely applied, nor evaluated by (independent) researchers. For universal use of a classification system, it is pivotal that the system is accessible, validated, reliable and reproducible.

Our report includes a summary of evaluation studies assessing these aspects in the different classification systems. Even though we retrieved 46 studies, the value of these evaluations is limited. Apart from the EFI score, the current classification systems have not been thoroughly assessed for validity, feasibility and reproducibility. Moreover, a significant proportion of the evaluation studies have examined the classification systems for purposes other than the one for which they were designed and initially evaluated.

Endometriosis is a challenging disease to classify, as it is known to have different phenotypes and presentations (both with regards to the type of lesions and their location), and various symptoms without a clear link to phenotype or presentation. Moreover, the natural progression of the disease is unknown. There is a perceived need for a validated classification or descriptive system for endometriosis that could support further progress in defining subgroups and more importantly guiding the therapeutic options for women with pain and/or infertility. Such a system would certainly also progress endometriosis research by unifying patient subgroups and facilitating the development of prognostic and predictive tools.

From this overview, it can be concluded that several classification, staging and reporting systems have been developed for endometriosis. A universally accepted categorization of the disease using the experience from the already existing proposals seems to be needed for clinical and research purposes.

Data availability

All data are incorporated into the article.

Acknowledgements

The authors would like to acknowledge the experts on endometriosis that contributed to the stakeholder review and thank them for their useful comments.

Authors' roles

N.V. performed the literature review and summarized the results. All other authors contributed to conception and design, drafting the content and critically revising it. All authors approved the final version.

Funding

The meetings and activities of the working group were funded by the American Association of Gynecologic Laparoscopists, European Society for Gynaecological Endoscopy, European Society of Human Reproduction and Embryology and World Endometriosis Society.

Conflict of interest

A.W.H. reports grant funding from the MRC, NIHR, CSO, Wellbeing of Women, Roche Diagnostics, Astra Zeneca, Ferring, Charles Wolfson Charitable Trust, Standard Life, Consultancy fees from Roche Diagnostics, AbbVie, Nordic Pharma and Ferring, outside the submitted work. In addition, A.W.H. has a patent Serum biomarker for endometriosis pending. N.P.J. reports personal fees from Abbott, Guerbet,

Myovant Sciences, Vifor Pharma, Roche Diagnostics, outside the submitted work; he is also President of the World Endometriosis Society and chair of the trust board. S.M. reports grants and personal fees from AbbVie, and personal fees from Roche outside the submitted work. C.T. reports grants, non-financial support and other from Merck SA, non-financial support and other from Gedeon Richter, non-financial support from Ferring Pharmaceuticals, outside the submitted work and without private revenue. K.T.Z. reports grants from Bayer Healthcare, MDNA Life Sciences, Roche Diagnostics Inc, Volition Rx, outside the submitted work; she is also a Board member (Secretary) of the World Endometriosis Society and World Endometriosis Research Foundation, Research Advisory Board member of Wellbeing of Women, UK (research charity), and Chair, Research Directions Working Group, World Endometriosis Society. The other authors had nothing to disclose.

References

- Acosta AA, Buttram VC Jr, Besch PK, Malinak LR, Franklin RR, Vanderheyden JD. A proposed classification of pelvic endometriosis. *Obstet Gynecol* 1973;**42**:19–25.
- Adamson GD, Pasta DJ. Endometriosis fertility index: the new, validated endometriosis staging system. *Fertil Steril* 2010;**94**:1609–1615.
- Adamson GD. Endometriosis classification: an update. *Curr Opin Obstet Gynecol* 2011;**23**:213–220.
- Aletaha D, Neogi T, Silman AJ, Felson MJ, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis* 2010;**69**:1580–1588.
- American Fertility Society. Classification of endometriosis. The American Fertility Society. *Fertil Steril* 1979;**32**:633–634.
- American Fertility Society. Revised American Fertility Society classification of endometriosis: 1985. *Fertil Steril* 1985;**43**:351–352.
- American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. *Fertil Steril* 1997;**67**:817–821.
- Andres MP, Borrelli GM, Abrao MS. Endometriosis classification according to pain symptoms: can the ASRM classification be improved? *Best Pract Res Clin Obstet Gynaecol* 2018;**51**:111–118.
- Barbosa MA, Teixeira DM, Navarro PA, Ferriani RA, Nastri CO, Martins WP. Impact of endometriosis and its staging on assisted reproduction outcome: systematic review and meta-analysis. *Ultrasound Obstet Gynecol* 2014;**44**:261–278.
- Becker CM, Laufer MR, Stratton P, Hummelshøj L, Missmer SA, Zondervan KT, Adamson GD; WERF EPHeCt Working Group. World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project: I. Surgical phenotype data collection in endometriosis research. *Fertil Steril* 2014; **102**:1213–1222.
- Boujenah J, Bonneau C, Hugues JN, Sifer C, Poncelet C. External validation of the Endometriosis Fertility Index in a French population. *Fertil Steril* 2015; **104**:119–123.e1.
- Boujenah J, Cedrin-Durnerin I, Herbemont C, Bricou A, Sifer C, Poncelet C. Use of the endometriosis fertility index in daily practice: a prospective evaluation. *Eur J Obstet Gynecol Reprod Biol* 2017;**219**:28–34.
- Bouquet de Joliniere J, Major A, Ayoubi JM, Cabry R, Khomsi F, Lesec G, Frydman R, Feki A. It is necessary to propose an add-on to the American Classification of Endometriosis? This disease can be compared to a malignant proliferation while remaining benign in most cases. EndoGram® is a new profile witness of its evolutionary potential. *Front Surg* 2019; **6**:27.
- Burla L, Scheiner D, Samartzis EP, Seidel S, Eberhard M, Fink D, Boss A, Imesch P. The ENZIAN score as a preoperative MRI-based classification instrument for deep infiltrating endometriosis. *Arch Gynecol Obstet* 2019; **300**:109–116.
- Buttram VC Jr. An expanded classification of endometriosis. *Fertil Steril* 1978; **30**:240–242.
- Candiani GB, Vercellini P, Fedele L. Laparoscopic ovarian puncture for correct staging of endometriosis. *Fertil Steril* 1990; **53**:994–997.
- Canis M, Pouly JL, Wattiez A, Manhes H, Mage G, Bruhat MA. Incidence of bilateral adnexal disease in severe endometriosis (revised American Fertility Society [AFS], stage IV): should a stage V be included in the AFS classification? *Fertil Steril* 1992; **57**:691–692.
- Chaabane S, Nguyen Xuan HT, Paternostre A, Du Cheyron J, Harizi R, Mimouni M, Fauconnier A. [Endometriosis: assessment of the Ultrasound-Based Endometriosis Staging System score (UBESS) in predicting surgical difficulty]. *Gynecol Obstet Fertil Senol* 2019; **47**:265–272.
- Chapron C, Dubuisson JB, Chopin N, Foulot H, Jacob S, Vieira M, Barakat H, Fauconnier A. [Deep pelvic endometriosis: management and proposal for a “surgical classification”]. *Gynecol Obstet Fertil* 2003a; **31**:197–206.
- Chapron C, Fauconnier A, Vieira M, Barakat H, Dousset B, Pansini V, Vacher-Lavenu MC, Dubuisson JB. Anatomical distribution of deeply infiltrating endometriosis: surgical implications and proposition for a classification. *Hum Reprod* 2003b; **18**:157–161.
- Chattot C, Huchon C, Paternostre A, Du Cheyron J, Chouillard E, Fauconnier A. ENDORECT: a preoperative score to accurately predict rectosigmoid involvement in patients with endometriosis. *Hum Reprod Open* 2019; **2019**:hoz007.
- Coccia ME, Rizzello F. Ultrasonographic staging: a new staging system for deep endometriosis. *Ann NY Acad Sci* 2011; **1221**:61–69.
- Denoix P. Nomenclature classification des cancers. *Bull Inst Nat Hyg(Paris)* 1952; **7**:743–748.
- Di Paola V, Manfredi R, Castelli F, Negrelli R, Mehrabi S, Pozzi Mucelli R. Detection and localization of deep endometriosis by means of MRI and correlation with the ENZIAN score. *Eur J Radiol* 2015; **84**:568–574.
- Edge SB, Byrd DR, Carducci MA, Compton CC, Fritz A, Greene F. *AJCC Cancer Staging Manual*. New York: Springer, 2010.
- Espada M, Leonardi M, Aas-Eng K, Lu C, Reyftmann L, Tetstall E, Slusarczyk B, Ludlow J, Hudelist G, Reid S et al. A multicenter international temporal and external validation study of the ultrasound-based endometriosis staging system. *J Minim Invasive Gynecol* 2020; **28**:57–62.
- Garavaglia E, Pagliardini L, Tandoi I, Sigismondi C, Vigano P, Ferrari S, Candiani M. External validation of the endometriosis fertility index (EFI) for predicting spontaneous pregnancy after surgery: further considerations on its validity. *Gynecol Obstet Invest* 2015; **79**:113–118.

- Guzick DS, Bross DS, Rock JA. Assessing the efficacy of The American Fertility Society's classification of endometriosis: application of a dose-response methodology. *Fertil Steril* 1982;38:171–176.
- Haas D, Chvatal R, Habelsberger A, Schimetta W, Wayand W, Shamiyah A, Oppelt P. Preoperative planning of surgery for deeply infiltrating endometriosis using the ENZIAN classification. *Eur J Obstet Gynecol Reprod Biol* 2013a;166:99–103.
- Haas D, Chvatal R, Habelsberger A, Wurm P, Schimetta W, Oppelt P. Comparison of revised American Fertility Society and ENZIAN staging: a critical evaluation of classifications of endometriosis on the basis of our patient population. *Fertil Steril* 2011;95:1574–1578.
- Haas D, Shebl O, Shamiyah A, Oppelt P. The rASRM score and the Enzian classification for endometriosis: their strengths and weaknesses. *Acta Obstet Gynecol Scand* 2013b;92:3–7.
- Hornstein MD, Gleason RE, Orav J, Haas ST, Friedman AJ, Rein MS, Hill JA, Barbieri RL. The reproducibility of the revised American Fertility Society classification of endometriosis. *Fertil Steril* 1993;59:1015–1021.
- Ichikawa M, Akira S, Kaseki H, Watanabe K, Ono S, Takeshita T. Accuracy and clinical value of an adhesion scoring system: A pre-operative diagnostic method using transvaginal ultrasonography for endometriotic adhesion. *J Obstet Gynaecol Res* 2020;46:466–478.
- Johnson NP, Hummelshøj L, Adamson GD, Keckstein J, Taylor HS, Abrao MS, Bush D, Kiesel L, Tamimi R, Sharpe-Timms KL et al. World Endometriosis Society Sao Paulo Consortium. World Endometriosis Society consensus on the classification of endometriosis. *Hum Reprod* 2017;32:315–324.
- Keckstein J, Saridogan E, Ulrich UA, Sillem M, Oppelt P, Schweppe Kw, Krentel H, Janschek E, Exacoustos C, Malzoni M et al. The #Enzian classification: a comprehensive non-invasive and surgical description system for endometriosis. *Acta Obstet Gynecol Scand* 2021;100:1165–1175.
- Kim JS, Lee CW, Yun J, Lee JH, Yun BH, Park JH, Seo SK, Cho S, Choi YS, Lee BS. Use of the endometriosis fertility index to predict natural pregnancy after endometriosis surgery: a single-center study. *Gynecol Obstet Invest* 2019;84:86–93.
- Kistner RW, Siegler AM, Behrman SJ. Suggested classification for endometriosis: relationship to infertility. *Fertil Steril* 1977;28:1008–1010.
- Knabben L, Imboden S, Fellmann B, Nirgianakis K, Kuhn A, Mueller MD. Urinary tract endometriosis in patients with deep infiltrating endometriosis: prevalence, symptoms, management, and proposal for a new clinical classification. *Fertil Steril* 2015;103:147–152.
- Kurata S, Ishimaru T, Masuzaki H, Yamabe T. Relationship between the prognosis of conception and the location of pelvic involvement in endometriosis: significance of the TOP (tube, ovary, peritoneum) classification. *Asia Oceania J Obstet Gynaecol* 1993;19:391–399.
- Lafay Pillet MC, Huchon C, Santulli P, Borghese B, Chapron C, Fauconnier AA. Clinical score can predict associated deep infiltrating endometriosis before surgery for an endometrioma. *Hum Reprod* 2014;29:1666–1676.
- Lasmar BR, Simoes Abraao M, Lasmar RB, Leon Dewilde R. Simplified approach to the treatment of endometriosis–ECO system. *Minerva Ginecol* 2012;64:331–335.
- Lasmar RB, Lasmar BP, Celeste RK, Larbig A, De Wilde RL. Validation of a score to guide endometriosis therapy for the non-specialized gynecologist. *Int J Gynaecol Obstet* 2015;131:78–81.
- Li X, Zeng C, Zhou YF, Yang HX, Shang J, Zhu SN, Xue Q. Endometriosis fertility index for predicting pregnancy after endometriosis surgery. *Chin Med J* 2017;130:1932–1937.
- Lim W, Ridge CA, Nicholson AG, Mirsadraee S. The 8(th) lung cancer TNM classification and clinical staging system: review of the changes and clinical implications. *Quant Imaging Med Surg* 2018;8:709–718.
- Lin SY, Lee RK, Hwu YM, Lin MH. Reproducibility of the revised American Fertility Society classification of endometriosis using laparoscopy or laparotomy. *Int J Gynaecol Obstet* 1998;60:265–269.
- Maheux-Lacroix S, Nesbitt-Hawes E, Deans R, Won H, Budden A, Adamson D, Abbott JA. Endometriosis fertility index predicts live births following surgical resection of moderate and severe endometriosis. *Hum Reprod* 2017;32:2243–2249.
- Marana R, Muzii L, Caruana P, Dell'Acqua S, Mancuso S. Evaluation of the correlation between endometriosis extent, age of the patients and associated symptomatology. *Acta Eur Fertil* 1991;22:209–212.
- Menakaya U, Reid S, Lu C, Gerges B, Infante F, Condous G. Performance of ultrasound-based endometriosis staging system (UBESS) for predicting level of complexity of laparoscopic surgery for endometriosis. *Ultrasound Obstet Gynecol* 2016;48:786–795.
- Milingos S, Protopapas A, Kallipolitis G, Drakakis P, Loutradis D, Liapi A, Antsaklis A. Endometriosis in patients with chronic pelvic pain: is staging predictive of the efficacy of laparoscopic surgery in pain relief? *Gynecol Obstet Invest* 2006;62:48–54.
- Miller-Keane OTM, O'Toole MT. *Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health*. Philadelphia, PA, USA: Elsevier Health Sciences, 2005.
- Morgan-Ortiz F, Lopez-de la Torre MA, Lopez-Zepeda MA, Morgan-Ruiz FV, Ortiz-Bojorquez JC, Bolivar-Rodriguez MA. Clinical characteristics and location of lesions in patients with deep infiltrating endometriosis: using the revised Enzian classification. *J Turk Ger Gynecol Assoc* 2018;20:133–137.
- Negi N, Roy KK, Kumar S, Nair VG, Vanamail P. Clinical outcome analysis and correlation of reproductive outcome with endometriosis fertility index in laparoscopically managed endometriosis patients: a retrospective cohort study. *J Hum Reprod Sci* 2019;12:98–103.
- Nicolaus K, Zschauer S, Bräuer D, Jimenez-Cruz J, Lehmann T, Rengsberger M, Diebolder H, Runnebaum IB. Extensive endometriosis surgery: rASRM and Enzian score independently relate to post-operative complication grade. *Arch Gynecol Obstet* 2020;301:699–706.
- Pal L, Shifren JL, Isaacson KB, Chang Y, Leykin L, Toth TL. Impact of varying stages of endometriosis on the outcome of in vitro fertilization-embryo transfer. *J Assist Reprod Genet* 1998;15:27–31.
- Pop-Trajkovic S, Popović J, Antić V, Radović D, Stefanović M, Stavanicic M, Vukomanović P. Stages of endometriosis: does it affect in vitro fertilization outcome. *Taiwan J Obstet Gynecol* 2014;53:224–226.
- Posadzka E, Jach R, Pityński K, Nocuń A. Ovarian reserve assessment in women with different stages of pelvic endometriosis. *Ginekol Pol* 2014;85:446–450.

- Radner H, Neogi T, Smolen JS, Aletaha D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. *Ann Rheum Dis* 2014; **73**:114–123.
- Riiskjær M, Egekvist AG, Hartwell D, Forman A, Seyer-Hansen M, Kesmodel US. Bowel Endometriosis Syndrome: a new scoring system for pelvic organ dysfunction and quality of life. *Hum Reprod* 2017; **32**:1812–1818.
- Rock JA, Guzick DS, Sengos C, Schweditsch M, Sapp KC, Jones HW Jr. The conservative surgical treatment of endometriosis: evaluation of pregnancy success with respect to the extent of disease as categorized using contemporary classification systems. *Fertil Steril* 1981; **35**:131–137.
- Rock JA. The revised American Fertility Society classification of endometriosis: reproducibility of scoring. ZOLADEX Endometriosis Study Group. *Fertil Steril* 1995; **63**:1108–1110.
- Rolla E. Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment. *F1000Res* 2019; **8**:529.
- Schliep KC, Chen Z, Stanford JB, Xie Y, Mumford SL, Hammoud AO, Boiman Johnstone E, Dorais JK, Varner MW, Buck Louis GM et al. Endometriosis diagnosis and staging by operating surgeon and expert review using multiple diagnostic tools: an inter-rater agreement study. *BJOG* 2017; **124**:220–229.
- Schliep KC, Stanford JB, Chen Z, Zhang B, Dorais JK, Boiman Johnstone E, Hammoud AO, Varner MW, Louis GM, Peterson CM. Interrater and intrarater reliability in the diagnosis and staging of endometriosis. *Obstet Gynecol* 2012; **120**:104–112.
- Sellers AH. The clinical classification of malignant tumours: the TNM system. *Can Med Assoc J* 1971; **105**:836 passim.
- Szendei G, Hernadi Z, Devenyi N, Csapo Z. Is there any correlation between stages of endometriosis and severity of chronic pelvic pain? Possibilities of treatment. *Gynecol Endocrinol* 2005; **21**: 93–100.
- Tomassetti C, Bafort C, Meuleman C, Welkenhuysen M, Fieuws S, D'Hooge T. Reproducibility of the Endometriosis Fertility Index: a prospective inter-/intra-rater agreement study. *BJOG* 2020; **127**: 107–114.
- Tomassetti C, Geysenbergh B, Meuleman C, Timmerman D, Fieuws S, D'Hooge T. External validation of the endometriosis fertility index (EFI) staging system for predicting non-ART pregnancy after endometriosis surgery. *Hum Reprod* 2013; **28**:1280–1288.
- Tompsett J, Leonardi M, Gerges B, Lu C, Reid S, Espada M, Condous G. Ultrasound-based endometriosis staging system: validation study to predict complexity of laparoscopic surgery. *J Minim Invasive Gynecol* 2019; **26**:477–483.
- Tuttlies F, Keckstein J, Ulrich U, Possover M, Schwepppe KW, Wustlich M, Buchweitz O, Greb R, Kandolf O, Mangold R et al. [ENZIAN-score, a classification of deep infiltrating endometriosis]. *Zentralbl Gynakol* 2005; **127**:275–281.
- van der Wat J, Kaplan MD, Roman H, Da Costa C. The use of modified virtual colonoscopy to structure a descriptive imaging classification with implied severity for rectogenital and disseminated endometriosis. *J Minim Invasive Gynecol* 2013; **20**:543–546.
- Vercellini P, Fedele L, Aimi G, De Giorgi O, Consonni D, Crosignani PG. Reproductive performance, pain recurrence and disease relapse after conservative surgical treatment for endometriosis: the predictive value of the current classification system. *Hum Reprod* 2006; **21**:2679–2685.
- Vercellini P, Fedele L, Aimi G, Pietropaolo G, Consonni D, Crosignani PG. Association between endometriosis stage, lesion type, patient characteristics and severity of pelvic pain symptoms: a multivariate analysis of over 1000 patients. *Hum Reprod* 2007; **22**: 266–271.
- Vesali S, Razavi M, Rezaeinejad M, Maleki-Hajiagha A, Maroufizadeh S, Sepidarkish M. Endometriosis Fertility Index for predicting non-assisted reproductive technology pregnancy after endometriosis surgery: a systematic review and meta-analysis. *BJOG* 2020; **127**: 800–809.
- Wang W, Li R, Fang T, Huang L, Ouyang N, Wang L, Zhang Q, Yang D. Endometriosis fertility index score maybe more accurate for predicting the outcomes of *in vitro* fertilisation than r-AFS classification in women with endometriosis. *Reprod Biol Endocrinol* 2013; **11**:112.
- Working group of ESGE ESHRE and WES Keckstein J, Becker CM, Canis M, Feki A, Grimbizis GF, Hummelshøj L, Nisolle M, Roman H, Saridogan E. Recommendations for the surgical treatment of endometriosis Part 2: deep endometriosis. *Facts Views Vis Obgyn* 2020a; **11**:269–297.
- Working group of ESGE ESHRE and WES, Keckstein J, Becker CM, Canis M, Feki A, Grimbizis GF, Hummelshøj L, Nisolle M, Roman H, Saridogan E et al. Recommendations for the surgical treatment of endometriosis. Part 2: deep endometriosis. *Hum Reprod Open* 2020b; **2020**:hoaa002.
- Working group of ESGE ESHRE and WES, Saridogan E, Becker CM, Feki A, Grimbizis GF, Hummelshøj L, Keckstein J, Nisolle M, Tanos V, Ulrich UA, Vermeulen N et al. Recommendations for the surgical treatment of endometriosis-part I: ovarian endometrioma. *Gynecol Surg* 2017a; **14**:27.
- Working group of ESGE ESHRE and WES, Saridogan E, Becker CM, Feki A, Grimbizis GF, Hummelshøj L, Keckstein J, Nisolle M, Tanos V, Ulrich UA et al. Recommendations for the Surgical Treatment of Endometriosis. Part I: Ovarian Endometrioma. *Hum Reprod Open* 2017b; **2017**:hox016.
- Yun BH, Jeon YE, Chon SJ, Park JH, Seo SK, Cho S, Choi YS, Lee JS, Lee BS. The prognostic value of individual adhesion scores from the Revised American Fertility Society Classification system for recurrent endometriosis. *Yonsei Med J* 2015; **56**:1079–1086.
- Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, Rienzi L, Sunde A, Schmidt L, Cooke ID et al. The international glossary on infertility and fertility care, 2017. *Hum Reprod* 2017; **32**:1786–1801.
- Zeng C, Xu JN, Zhou Y, Zhou YF, Zhu SN, Xue Q. Reproductive performance after surgery for endometriosis: predictive value of the revised American Fertility Society classification and the endometriosis fertility index. *Gynecol Obstet Invest* 2014; **77**:180–185.
- Zhang X, Liu D, Huang W, Wang Q, Feng X, Tan J. Prediction of Endometriosis Fertility Index in patients with endometriosis-associated infertility after laparoscopic treatment. *Reprod Biomed Online* 2018; **37**:53–59.
- Zhou Y, Lin L, Chen Z, Wang Y, Chen C, Li E, Wu R. Fertility performance and the predictive value of the endometriosis fertility index staging system in women with recurrent endometriosis: a retrospective study. *Medicine (Baltimore)* 2019; **98**:e16965.
- Zondervan KT, Becker CM, Missmer SA. Endometriosis. *N Engl J Med* 2020; **382**:1244–1256.